IBD Research Resource Center

Clinical ID	c3114
Identifier	ACTRN12613001347752
Trial Title	A randomized controlled trial of patients with IBD attending specialist clinics comparing de novo combination allopurinol and thiopurine versus thiopurine and placebo (ie standard practice) in terms of objective and clinical outcomes at six months
Trial URL	Visit Original Page

Study Results	No results available
Conditions	Inflammatory Bowel Disease; Inflammatory Bowel Disease;Oral and Gastrointestinal - Inflammatory bowel disease;Inflammatory and Immune System - Other inflammatory or immune system disorders
Interventions	De novo combination therapy with allopurinol 100mg orally and gradual pre-specified dose increments of azathioprine (or mercaptopurine) starting at 50mg (or 25mg) orally daily as determined by measuring thiopurine metabolite levels at week 14 and the absence of serious side effects. The decision to commence azathioprine or mercaptopurine will be at the discretion of the treating clinician as per their standard practice. Medications will be supplied in sealed non-distinguishable treatment bottles which will be supplied every eight weeks and drug/ packaging will be returned to assess adherence at the relevant study visit(s). The overall duration of study treatment will be six months.

Sex Requirement	ALL
Age Requirement	ADULT, ELDER, OLDER_ADULT

Study Type	Interventional
Phase	PHASE3\|PHASE4